GenSight Biologics S.A.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its pr…
Biotechnology
FR, Paris [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 0.77 | 0.77 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -10.07 | -4.29 | -3.90 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | -0.30 | -0.30 | |
| Cash | 0.00 | 0.08 | 0.08 | |
| Capex | 0.00 | < 0.005 | < 0.005 | |
| Free Cash Flow | 0.00 | -0.04 | -0.04 | |
| Revenue | 0.00 | 0.01 | 0.01 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 1.00 | 1.00 | |
| Operating Margin | 0.00 | -4.28 | -4.28 | |
| ROA | 0.00 | -0.20 | -0.20 | |
| ROE | 0.00 | 0.12 | 0.12 | |
| ROIC | 0.00 | 1.03 | 1.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of SIGHT.PA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of SIGHT.PA is permitted for members.
6
Leverage & Liquidity